emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension

Janelle Yorke, Paul Corris, Sean Gaine, J Simon R Gibbs, David G Kiely, Carl Harries, Val Pollock, Iain Armstrong, Janelle Yorke, Paul Corris, Sean Gaine, J Simon R Gibbs, David G Kiely, Carl Harries, Val Pollock, Iain Armstrong

Abstract

The aim of this study was to develop a measure of the impact of pulmonary hypertension (PH) on health-related quality of life (HRQoL) as there is a need for a short, validated instrument that can be used in routine clinical practice. Interviews were conducted with 30 PH patients to derive 32 statements, which were presented as a semantic differential six-point scale (0-5), with contrasting adjectives at each end. This item list was completed by patients attending PH clinics across the UK and Ireland. Rasch analysis was applied to identify items fitting a uni-dimensional model. 226 patients (mean age 55.6±14 years; 70% female) with PH (82% had pulmonary arterial hypertension) completed the study questionnaires. 10 of the 32 items demonstrated fit to the Rasch model (Chi-squared 16; p>0.05) and generated the emPHasis-10 questionnaire. Test-retest (intraclass correlation coefficient 0.95, n=33) and internal consistency (Chronbach's α=0.9) were strong. emPHasis-10 scores correlated consistently with other relevant measures and discriminated subgroups of patients stratified by World Health Organization functional class (ANOVA F=1.73; p<0.001). The emPHasis-10 is a short questionnaire for assessing HRQoL in pulmonary arterial hypertension. It has excellent measurement properties and is sensitive to differences in relevant clinical parameters. It is freely available for clinical and academic use.

Conflict of interest statement

Conflict of interest: Disclosures can be found alongside the online version of this article at www.erj.ersjournals.com

Figures

Figure 1–
Figure 1–
Distribution of a) patients and b) items based on Rasch logit locations showing the distributions of patient health-related quality of life severity and item severity (locations) along the same linear scale measured in logits. Most items are located between -2 and +2 logits. Total n=226, mean±sd 0.200±1.334.
Figure 2–
Figure 2–
The final emPHasis-10 questionnaire. The Pulmonary Hypertension Association UK (Rotherham, UK) intends to make this questionnaire free to use by both the clinical and academic communities. It can be downloaded free of charge from the Pulmonary Hypertension Association UK website (www.phassociation.uk.com) and reproduced without cost for clinical and academic use. Different language versions will be made available in due course. Reproduced with permission from the Pulmonary Hypertension Association UK.
Figure 3–
Figure 3–
Mean emPHasis-10 scores for each World Health Organization (WHO) functional class. Error bars represent 95% confidence intervals.

References

    1. Yi L, Johnson M, Kiely DG, et al. Changing demographics and epidemiology of incident idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 186: 790–796
    1. Hurdman J, Condliffe R, Elliot CA, et al. ASPIRE Registry: assessing the spectrum of pulmonary hypertension identified at a referral centre. Eur Respir J 2012; 39: 945–955
    1. Kiely DG, Elliot CA, Sabroe I, et al. Pulmonary hypertension: diagnosis and management. BMJ 2013; 346: f2028.
    1. Armstrong I, Harries C, Rochnia N, et al. The trajectory to diagnosis with pulmonary hypertension: a qualitative study. BMJ Open 2012; 2: e000806
    1. McDonough A, Matura LA, Carroll DL. Symptom experience of pulmonary arterial hypertension patients. Clin Nurs Res 2011; 20: 120–134
    1. Lowe B, Grafe K, Ufer C, et al. Anxiety and depression in patients with pulmonary hypertension. Psychosom Med 2004; 66: 831–836
    1. Flattery MP, Pinson JM, Savage L, et al. Living with pulmonary arterial hypertension: patient’s experiences. Heart Lung 2005; 34: 99e107.
    1. McKenna SP, Doughty N, Meads DM, et al. The Cambridge pulmonary hypertension outcome review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 2006; 15: 103–115
    1. Ware JE, Kosinski M, Dewey JE, How to score version 2 of the SF-36 health survey. Lincoln, QualityMetric Incorporated, 2000
    1. Hunt SM, McEwan J. The development of a subjective health indicator. Soc Health Illness 1980; 2: 231–246
    1. Rector TS, Kubo SH, Cohn JN. Patients’ self-assessment of their congestive heart failure. Part 2: Content, reliability and validity of a new measure, the Minnesota Living with Heart Failure questionnaire. Heart Failure 1987; 3: 198–209
    1. Gomberg-Maitlan M, Thenaappan T, Rizvi K, et al. United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). J Heart Lung Trasplant 2008; 27: 124–130
    1. Coffin D, Duval K, Martel S, et al. Adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) into French-Canadian and English-Canadian. Can Respir J 2008; 15: 77–83
    1. Ganderton L, Jenkins S, McKenna SP, et al. Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Australian and New Zealand population. Respirology 2011; 16: 1235–1240
    1. Taichman DB, Shin J, Hud J, et al. Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res 2005; 6: 92.
    1. Suntharalingam J, Treacy CM, Doughty NJ, et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest 2008; 229–236
    1. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009; 30: 2493–2537
    1. Drennan J. Cognitive interviewing: verbal data in the design and pretesting of questionnaires. J Adv Nurs 2003; 42: 57–63
    1. Cenedese E, Speich R, Dorschner S, et al. Measurement of quality of life in pulmonary hypertension and its significance. Eur Respir J 2006; 28: 808–815
    1. Zlupko M, Harhay MO, Gallop R, et al. Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension. Respir Med 2008; 102: 1431–1438
    1. Yorke J, Moosavi SH, Shuldham C, et al. Quantification of breathlessness using descriptors: development and initial testing of Dyspnoea-12. Thorax 2010; 65: 21–26
    1. Yore J, Armstrong I. The assessment of breathlessness in pulmonary arterial hypertension: reliability and validity of the Dyspnoea-12. Eur J Cardiovasc Nurs 2013 [In press DOI: 10.1177/1474515113514891]
    1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scandinavica 1983; 67: 361–370
    1. Yorke J, Horton M, Jones PW. A critique of Rasch analysis using the Dyspnoea-12 as an illustrative example. J Adv Nurs 2011; 68: 191–98
    1. O’Leary CJ, Jones PW. The influence of decisions made by developers on health status questionnaire content. Qual Life Res 1998; 7: 545–550
    1. Rattray J, Jones MC. Essential elements of questionnaire design and development. J Clin Nurs 2007; 16: 234–243
    1. Pallant JF, Tennant A. An introduction to the Rasch measurement model: an example using the Hospital Anxiety and Depression Scale (HADS). Br J Clin Psychol 2007; 46: 1–18
    1. Cronbach L. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 22: 293e6
    1. Bland J, Altman D. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307e10.
    1. Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J 2009; 34: 648–654

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever